Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David G. Barrett is active.

Publication


Featured researches published by David G. Barrett.


Journal of Medicinal Chemistry | 2002

Synthesis and evaluation of potent and selective β3 adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres

David E. Uehling; Kelly Horne Donaldson; David N. Deaton; Clifton E. Hyman; Elizabeth E. Sugg; David G. Barrett; Robert G. Hughes; Barbara E. Reitter; Kim K. Adkison; Mary E. Lancaster; Frank Lee; Robert Hart; Mark A. Paulik; Bryan W. Sherman; Timothy A. True; Conrad Cowan


Archives of Biochemistry and Biophysics | 2002

Expression, preparation, and high-throughput screening of caspase-8: discovery of redox-based and steroid diacid inhibition.

Gary K. Smith; David G. Barrett; Kevin Blackburn; Michael Cory; Walter S. Dallas; Roderick G. Davis; Daniel F. Hassler; Randy T. McConnell; Mary Moyer; Kurt Weaver


Bioorganic & Medicinal Chemistry Letters | 2005

P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.

David G. Barrett; Virginia M. Boncek; John G. Catalano; David N. Deaton; Anne M. Hassell; Cynthia Holder Jurgensen; Stacey T. Long; Robert B. McFadyen; Aaron B. Miller; Larry R. Miller; J. Alan Payne; John A. Ray; Vicente Samano; Lisa M. Shewchuk; Francis X. Tavares; Kevin J. Wells-Knecht; Derril H. Willard; Lois L. Wright; Hui-Qiang Q. Zhou


Bioorganic & Medicinal Chemistry Letters | 2004

Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.

David G. Barrett; John G. Catalano; David N. Deaton; Anne M. Hassell; Stacey T. Long; Aaron B. Miller; Larry R. Miller; Lisa M. Shewchuk; Kevin J. Wells-Knecht; Derril H. Willard; Lois L. Wright


Journal of Organic Chemistry | 1998

DEGRADATIVE REARRANGEMENTS OF N-(T-BUTYLOXYCARBONYL)-O-METHANESULFONYL-HYDROXAMIC ACIDS : A NOVEL, REAGENT-BASED ALTERNATIVE TO THE LOSSEN REARRANGEME NT

Jeffrey A. Stafford; Stephen S. Gonzales; David G. Barrett; Edward Martin Suh; Paul L. Feldman


Bioorganic & Medicinal Chemistry Letters | 2005

Acyclic cyanamide-based inhibitors of cathepsin K.

David G. Barrett; David N. Deaton; Anne M. Hassell; Robert B. McFadyen; Aaron B. Miller; Larry R. Miller; J. Alan Payne; Lisa M. Shewchuk; Derril H. Willard; Lois L. Wright


Bioorganic & Medicinal Chemistry Letters | 2006

Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.

David G. Barrett; John G. Catalano; David N. Deaton; Anne M. Hassell; Stacey T. Long; Aaron B. Miller; Larry R. Miller; John A. Ray; Vicente Samano; Lisa M. Shewchuk; Kevin J. Wells-Knecht; Derril H. Willard; Lois L. Wright


Bioorganic & Medicinal Chemistry Letters | 2004

Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.

David G. Barrett; John G. Catalano; David N. Deaton; Stacey T. Long; Larry R. Miller; Francis X. Tavares; Kevin J. Wells-Knecht; Lois L. Wright; Hui-Qiang Q. Zhou


Bioorganic & Medicinal Chemistry Letters | 2006

Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

Kim K. Adkison; David G. Barrett; David N. Deaton; Robert T. Gampe; Anne M. Hassell; Stacey T. Long; Robert B. McFadyen; Aaron B. Miller; Larry R. Miller; J. Alan Payne; Lisa M. Shewchuk; Kevin J. Wells-Knecht; Derril H. Willard; Lois L. Wright


Archive | 2002

Alpha-ketoamide derivatives as cathepsin k inhibitors

David G. Barrett; David N. Deaton; Robert B. McFadyen; Aaron B. Miller; John A. Ray; Francis X. Tavares; Huiqiang Zhou

Collaboration


Dive into the David G. Barrett's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge